Literature DB >> 21695747

The psychosocial impact of an abnormal cervical smear result.

Mélanie Drolet1, Marc Brisson, Elizabeth Maunsell, Eduardo L Franco, François Coutlée, Alex Ferenczy, William Fisher, James A Mansi.   

Abstract

BACKGROUND: Data on the impact of abnormal cervical smear results on health-related quality of life (HrQoL) are scarce. We aimed to (i) prospectively assess the HrQoL of women who were informed of an abnormal smear result; (ii) identify predictors of greater negative psychosocial impact of an abnormal result; and (iii) prospectively estimate the quality-adjusted life-years (QALYs) lost following an abnormal result.
METHODS: Between 08/2006 and 08/2008, 492 women with an abnormal result and 460 women with a normal result, frequency matched for age and clinic, were recruited across Canada. HrQoL was measured at recruitment and 4 and 12 weeks later with the EuroQol, Short Form-12, short Spielberg State-Trait Anxiety Inventory (STAI) and HPV Impact Profile. Three blocks of potential predictors of higher psychosocial impact were tested by hierarchical modeling: (i) socio-demographics; (ii) sexual activity; and (iii) smear result severity, communication, and understanding.
RESULTS: Receiving an abnormal result significantly increased anxiety (STAI mean difference between both groups = 8.3). Initial anxiety decreased over time for the majority of women. However, 35% of women had clinically meaningful anxiety at 12 weeks (i.e. STAI scores ≥0.5 standard deviation of the controls). These women reported a lower socio-economic level, did not completely understand the information about their result and perceived themselves at higher risk of cancer. QALY lost following an abnormal result were between 0.007 and 0.009.
CONCLUSIONS: Receiving an abnormal smear has a statistically significant and clinically meaningful negative impact on mental health. However, this negative impact subsides after 12 weeks for the majority of women.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21695747     DOI: 10.1002/pon.2003

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  29 in total

1.  Excess Cost of Cervical Cancer Screening Beyond Recommended Screening Ages or After Hysterectomy in a Single Institution.

Authors:  Deanna Teoh; Gretchen Hultman; McKenzie DeKam; Rachel Isaksson Vogel; Levi S Downs; Melissa A Geller; Chap Le; Genevieve Melton; Shalini Kulasingam
Journal:  J Low Genit Tract Dis       Date:  2018-07       Impact factor: 1.925

2.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

Review 3.  Health-related quality of life as measured by the EQ-5D in the prevention, screening and management of cervical disease: A systematic review.

Authors:  A Ó Céilleachair; J F O'Mahony; M O'Connor; J O'Leary; C Normand; C Martin; L Sharp
Journal:  Qual Life Res       Date:  2017-06-26       Impact factor: 4.147

4.  Impact of coverage-dependent marginal costs on optimal HPV vaccination strategies.

Authors:  Marc D Ryser; Kevin McGoff; David P Herzog; David J Sivakoff; Evan R Myers
Journal:  Epidemics       Date:  2015-02-07       Impact factor: 4.396

5.  Do invitations for cervical screening provide sufficient information to enable informed choice? A cross-sectional study of invitations for publicly funded cervical screening.

Authors:  Sie Karen Kolthoff; Mie Sara Hestbech; Karsten Juhl Jørgensen; John Brodersen
Journal:  J R Soc Med       Date:  2016-04-26       Impact factor: 5.344

6.  The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.

Authors:  Harrell W Chesson; Lauri E Markowitz; Susan Hariri; Donatus U Ekwueme; Mona Saraiya
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

7.  Harms of cervical cancer screening in the United States and the Netherlands.

Authors:  Dik Habbema; Sheila Weinmann; Marc Arbyn; Aruna Kamineni; Andrew E Williams; Inge M C M de Kok; Folkert van Kemenade; Terry S Field; Joost van Rosmalen; Martin L Brown
Journal:  Int J Cancer       Date:  2017-03-01       Impact factor: 7.396

Review 8.  Does treatment for cervical and vulvar dysplasia impact women's sexual health?

Authors:  Blanca R Cendejas; Karen K Smith-McCune; Michelle J Khan
Journal:  Am J Obstet Gynecol       Date:  2014-05-29       Impact factor: 8.661

9.  Psychological factors among Appalachian women with abnormal Pap results.

Authors:  Adebola Adegboyega; Mark Dignan; Shuying Sha; Chigozie Nkwonta; Lovoria B Williams
Journal:  J Rural Health       Date:  2021-05-06       Impact factor: 4.333

10.  Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness?

Authors:  Mélanie Drolet; Marie-Claude Boily; Nicolas Van de Velde; Eduardo L Franco; Marc Brisson
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.